ESMO 2025: Data, decisions, and the future of oncology
Leading clinicians, researchers, and pharmaceutical innovators gathered at the ESMO Congress 2025 to discuss the future of cancer treatment.
The event, held in Berlin, showcased remarkable progress in oncology, including next-generation immunotherapies, antibody-drug conjugates (ADCs), and AI-driven precision medicine.
Advances in tumor-agnostic therapies and novel checkpoint inhibitors are reshaping expectations for patient outcomes, particularly in lung, breast, and gastrointestinal cancers.
The ESMO Congress 2025 once again demonstrated why it stands at the forefront of global oncology.
The congress reaffirmed ESMO’s status as a defining moment in the oncology calendar, where new science meets strategic insight.
Author's summary: ESMO Congress 2025 highlights progress in cancer treatment.
More News
- Election Guide 2025: Nassau County Legislature District 7 candidate Alec Fischthal, Dem.
- Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times - Clinical Insights for Eye Specialists
- AirAsia parent Capital A revives Nasdaq IPO plan for subsidiary
- STORM WATCH: Strong wind gusts up to 50 mph, heavy rain passes across NJ today
- Liberals Panic as Trump Eyes Potential Third Term
- Vucic, Pellegrini meet in Samarkand
- Letters | Fractured leadership - Navajo Times
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- What happens when BLACKPINK comes to town?
- Aspiring Teacher, Student Leader, Lacrosse Standout, Tess Brown ’26 Selected to Attend NCAA Program